| Name | Title | Contact Details |
|---|
4Liberty is a leading technical & professional services firm focused on energy & infrastructure. We manage large scale programs and projects for diverse clients across North America. We help utilities through the energy transition necessary to meet customer expectations, adhere to government mandates, and reach sustainable goals. We help commercial, government, and municipal customers implement the modern infrastructure needed to bolster security, improve connectivity, and ensure environmental and social justice.
Icreon is a leading customer experience transformation company providing organizations with digital strategy consulting, design, and engineering services at scale. Founded in 2000 and headquartered in New York with offices in London and New Delhi, Icreon specializes in serving Fortune 500 clients including industry leaders like Johnson Controls, Acrisure, Jets.com to the Major League Baseball Players Association. Fortune 500 companies, growing brands, and non-profits partner with Icreon to enable their next phase of growth through digital.
DAST Consulting Services is a rapidly growing company that is part of a consortium of organizations with a vision to unlock financial resources so that every kid in America has access to a Christ-centered education. We collaborate with accredited non-public schools to help them leverage various revenue streams, including federal and state grant funding programs as well as innovative work-based learning initiatives. DAST also has an active venture studio (DAST Investments) with multiple portfolio companies, and a nonprofit (DAST Foundation) that recently launched a Classical Christian Microschool network.
PaulHood goes beyond basic tax preparation. We nurture all aspects of financial health, offering peace of mind and proactive solutions tailored to your unique individual and business needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.